GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

Inclusion Criteria

• •Histologically or cytologically confirmed adenocarcinoma of the prostate
• •Clinical or radiologic evidence of metastatic disease
• •Documented disease progression during hormone therapy (ADT plus antiandrogen) and no response to ADT withdrawal
• •Docetaxel-refractory disease defined as disease progression documented either during treatment of within 60 days after the cessation of treatment with docetaxel
• •Prior exposure to estramustine or mitoxantrone is allowed
• •KPS ≥ 60
• •No prior radioisotope therapy
• •No prior radiotherapy 25% or more of the bone marrow
• •No peripheral neuropathy grade 2 or worse
• •Adequate organ and bone marrow function